Operant Conditioning for Rehabilitation After Stroke
Launched by UNIVERSITY OF HOUSTON · Aug 20, 2021
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a rehabilitation method for people who have had a stroke. The researchers want to understand how certain muscles work together after a stroke and whether they can be improved through a technique called motor evoked potential conditioning. This method aims to help the wrist muscles, specifically the extensor carpi radialis, regain function by encouraging the brain to adapt and change, which is known as corticospinal plasticity.
To participate, you need to be between 40 and 75 years old and have had a stroke that affects one side of your body. You should have had your stroke more than six months ago and have some weakness in your wrist. However, you cannot have other neurological disorders, serious cognitive issues, or certain medical devices in your body, among other criteria. If you join the study, you can expect to undergo sessions that focus on improving your wrist movement and coordination with the help of specialists. This research is currently looking for participants, and it could be a chance to contribute to new methods for stroke rehabilitation.
Gender
ALL
Eligibility criteria
- • Inclusion criteria for aged matched healthy group
- • Male or female whose age range between 40 and 75
- • no known neurological injuries
- • Exclusion criteria for aged matched healthy group
- • have an orthopedic disorder involving upper limbs;
- • have a history of any neurologic disease;
- • have any history of epilepsy of the potential participants and/or their family members;
- • had an adverse reaction to TMS;
- • are unable to consent;
- • are pregnant.
- • Inclusion criteria for stroke group
- • male or female hemiparetic chronic stroke survivors;
- • age ranging between 40-75 year;
- • with single unilateral ischemic or hemorrhagic middle cerebral artery stroke;
- • neurologically stable for \>6 months;
- • have an expectation that current medication will be maintained without changes for at least 3 months. Stable use of anti-spasticity medication (e.g., baclofen, diazepam, tizanidine) is accepted;
- • with moderate-to-severe impairments (FMA\<45/66);
- • with weak wrist extension (i.e., \<4 by manual muscle strength test);
- • eligible to receive transcranial magnetic stimulation (TMS), and extensor carpi radialis (ECR) motor evoked potential (MEP) must be present in the more affected arm;
- • without severe spasticity (Modified Ashworth (MA) \<4);
- • have not received botulinum toxin on the impaired arm within 3 months.
- • Exclusion criteria for stroke group
- • have an orthopedic disorder involving upper limbs;
- • have no measurable MEP elicited in the ECR;
- • unable to produce any voluntary ECR EMG activity;
- • cognitive impairment sufficient to interfere with informed consent or successful completion of the protocol (Montreal Cognitive Assessment (MoCA) score \< 26);
- • a history of another neurologic disease;
- • a history of vertigo;
- • a history of vestibular or cochlear dysfunction;
- • have a history of convulsion or a seizure;
- • anesthesia of joint position sense in upper limbs;
- • are pregnant or have a chance that they might be (self-reported);
- • have metal in the brain/skull (except titanium; e.g. splinters, fragments, clips, etc.);
- • have cochlear implants;
- • have an implanted neurostimulator (DBS, epidural/subdural, VNS);
- • have a cardiac pacemaker or intracardiac lines or metal in the body;
- • have a medication infusion device;
- • are taking any medications to treat mental illness;
- • have spinal or ventricular derivations;
- • had an adverse reaction to TMS.
About University Of Houston
The University of Houston is a leading research institution dedicated to advancing knowledge and innovation across various disciplines, including clinical research. With a commitment to enhancing public health and well-being, the university actively sponsors clinical trials that explore new treatments and interventions. Leveraging its robust academic resources and expertise, the University of Houston fosters collaboration among researchers, healthcare professionals, and community partners to address pressing health challenges and contribute valuable insights to the medical field. Through its clinical trial initiatives, the university aims to translate research findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Jinsook Roh, Ph.D.
Principal Investigator
University of Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials